Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer

CONCLUSIONS: Olaparib plus ceralasertib is well-tolerated. No objective responses occurred, though a signal of activity was seen particularly in disease associated with BRCA1. Further evaluation of this combination should include alternate dosing strategies in genomically-selected populations.PMID:34620496 | DOI:10.1016/j.ygyno.2021.08.024

Source: Gynecologic Oncology - October 8, 2021 Category: Cancer & Oncology Authors: Payal D Shah Stephanie L Wethington Cheyenne Pagan Nawar Latif Janos Tanyi Lainie P Martin Mark Morgan Robert A Burger Ashley Haggerty Haley Zarrin Diego Rodriguez Susan Domchek Ronny Drapkin Ie-Ming Shih Simon A Smith Emma Dean St éphanie Gaillard Debor Source Type: research